Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Beginners’ Portfolio: What Have Vodafone Group plc, GlaxoSmithKline plc And Barclays PLC Done For Our Blue-Chip Prospects?

How did blue-chip purchases of Vodafone Group plc (LON: VOD), GlaxoSmithKline plc (LON: GSK) and Barclays PLC (LON: BARC) pan out?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, run as if based on real money with all costs, spreads and dividends accounted for. Transactions made for the portfolio are for educational purposes only and do not constitute advice to buy or sell.

When I started the Beginners’ Portfolio my intention was to go for a combination of blue-chip dividend-paying shares and growth shares, and the success so far has been mixed with both approaches. Today I’m going to look at the blue-chip portion of the portfolio, paying special attention to one share I’ve since sold and two I still keep.

Telecoms profit

I sold Vodafone (LSE: VOD) back in December 2013 at a price of 234p, mainly because I thought its undervaluation was out by then, and partly because voice revenues were falling and I didn’t see a clear forward strategy for the company. As it happened, the timing worked out pretty well, and the portfolio made a capital gain of £166.46 with dividends of £58.35 added to the pot — a very nice overall gain of 45% over a 19-month period, after accounting for all costs.

Since then the price has been erratic and today is a little higher at 244p, but I think I made the right decision at the time.

Pharma laggard

GlaxoSmithKline (LSE: GSK) has not worked out as well as I thought it would have by now since I bought it in June 2012. In fact, if I sold at today’s 1,409p level I’d realise a loss on the share price of 6.6% — although total dividends of £79.56 would swing that to a modest total 9.2% gain after costs.

I thought the prospects of a return to earnings growth in 2016 would have improved sentiment towards Glaxo by now, but until that happens I’m happy to hold and keep taking dividend yields of around 6%.

Banking on banking

As the banking sector returned to health, I decided I wanted one to help give us a balanced portfolio, and I went for Barclays (LSE: BARC) in February 2014. Since then we’ve enjoyed a 6.7% gain (after costs) from a share price rise to 282p, with £15.75 in dividends taking the total gain to 9.6%.

One of my big reasons for choosing Barclays was its recovering dividend. It only yielded 2.7% in 2014 but it was very well covered. And we have EPS growth of around 33% forecast for this year, followed by another 20% in 2016, which makes me think we’re still in early days of Barclays’ recovery — and it was a good time to get in.

Bottom line

How has the blue-chip portion of the portfolio performed overall? I couldn’t finish without mentioning the overall 18% loss I took when I dumped Tesco, eased a little by some dividends in the early days. BP has been pretty flat with a total return of 2.8%, Rio Tinto is disappointingly down 13%, again softened by decent dividends, BAE Systems is sitting pretty with a very nice 54% overall gain, and Aviva has given us an even better 74% gain so far.

The blue-chip portion of the portfolio is up 16% after considering the effects of all costs (including the cost of selling the whole lot today). For an average holding time of around a couple of years, that compares reasonably well to the 10% or so we’d have gained from a FTSE 100 tracker over a similar period.

Next time I’ll take a look at the portfolio’s growth stocks.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended Barclays and GlaxoSmithKline, and owns shares in Tesco. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

3 Warren Buffett investing ideas I plan to use in 2026

After decades in the top job at Berkshire Hathaway, Warren Buffett is preparing to step aside. But this writer will…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

Looking to earn a second income next year (and every year)? Here’s one approach.

Christopher Ruane explains how some prudent investment decisions now could potentially help set someone up with a second income in…

Read more »

Senior woman potting plant in garden at home
Investing Articles

Could a 10%+ yielding dividend share like this make sense for a retirement portfolio?

With a double-digit percentage yield, could this FTSE 250 share be worth considering for a retirement portfolio? Our writer weighs…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Forget Rigetti and IonQ: here’s a quantum computing growth stock that actually looks cheap

Edward Sheldon has found a growth stock in the quantum computing space with lots of potential and a really attractive…

Read more »

UK money in a Jar on a background
Investing Articles

Here’s a £3 a day passive income plan for 2026!

Looking for a simple and cheap plan to try and earn passive income in 2026 and beyond? Christopher Ruane shares…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

NIO stock’s down 35% since October. Time to buy?

NIO stock has had a roller coaster year so far! Christopher Ruane looks at some of the highs and lows…

Read more »

Investing Articles

By December 2026, £1,000 invested in BAE Systems shares could be worth…

Where will BAE Systems shares be in a year's time? Here is our Foolish author's review of the latest analyst…

Read more »

Mature people enjoying time together during road trip
Investing Articles

Keen for early retirement with a second income from dividends? Here’s how much you might need to invest

Ditching the office job early is a dream of many, but without a second income, is it possible? Here’s how…

Read more »